Gastric Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

GASC MCID: GST053 MIFTS: 78	Gastric Cancer (GASC) Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer ⁵⁸ ³⁹ ¹² ⁵⁴ ⁷⁶ ³⁸ ⁵⁶ ¹⁵

Stomach Cancer ¹² ⁷⁷ ⁵⁴ ⁷⁶ ³⁰ ⁴⁴ ¹⁵

Stomach Carcinoma ¹² ⁵⁴ ¹⁵ ⁷⁴

Gastric Carcinoma ¹² ⁵⁶ ¹⁵ ¹⁷

Malignant Tumor of Lesser Curve of Stomach ¹² ⁷⁴

Malignant Neoplasm of Body of Stomach ¹² ⁷⁴

Stomach Neoplasms ⁴⁵ ⁷⁴

Malignant Neoplasm of Lesser Curve of Stomach ¹²

Malignant Tumor of Greater Curve of Stomach ¹²

Malignant Tumor of Body of Stomach ¹²

Ca Greater Curvature of Stomach ¹²

Ca Lesser Curvature - Stomach ¹²

Malignant Neoplasm of Stomach ⁷⁴

Gastric Cancer Intestinal ⁷⁶

Gastric Cancer, Somatic ⁵⁸

Adult Stomach Carcinoma ⁵⁴

Cancer of the Stomach ¹²

Carcinoma of Stomach ¹²

Adult Stomach Cancer ⁵⁴

Ca Body - Stomach ¹²

Gastric Neoplasm ¹²

Stomach Neoplasm ¹⁷

Cancer, Gastric ⁴¹

Gasc ⁷⁶

Characteristics:

HPO:

³³

gastric cancer:
Inheritance somatic mutation

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of stomach

Malignant neoplasm: Body of stomach

Malignant neoplasm: Greater curvature of stomach, unspecified

Malignant neoplasm: Lesser curvature of stomach, unspecified

Malignant neoplasm: Stomach, unspecified

External Ids:

Disease Ontology ¹² DOID:10534 DOID:5517

OMIM ⁵⁸ 613659

KEGG ³⁸ H00018

ICD9CM ³⁶ 151 151.4 151.5 more

MeSH ⁴⁵ D013274

NCIt ⁵¹ C3387 C4911 C9331

SNOMED-CT ⁶⁹ 93717002 93818001 93867004 more

ICD10 ³⁴ C16 C16.2 C16.5 more

MedGen ⁴³ C0699791 C3150911

SNOMED-CT via HPO ⁷⁰ 124975008 372143007

EFO ¹⁷ EFO_0000178 EFO_0003897

UMLS ⁷⁴ C0024623 C0038356 C0153421 more

Sources

Summaries for Gastric Cancer

NIH Rare Diseases : ⁵⁴ Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : ¹² A gastrointestinal system cancer that is located in the stomach.

OMIM : ⁵⁸ In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : ⁴⁴ The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : ⁷⁶ Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : ⁷⁷ Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Sources

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)

#	Related Disease	Score	Top Affiliating Genes
1	gastric adenocarcinoma	33.7	APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
2	colorectal cancer	32.5	APC CTNNB1 ERBB2 KRAS MIR106B MIR141
3	adenocarcinoma	32.4	APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
4	breast cancer	32.4	APC CTNNB1 ERBB2 FGFR2 KRAS MIR141
5	prostate cancer	32.0	CTNNB1 ERBB2 FGFR2 KLF6 KRAS MIR106B
6	hepatocellular carcinoma	31.9	APC CTNNB1 KRAS MIR106B MIR141 MIR145
7	esophageal cancer	31.9	CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR34A
8	lung cancer	31.9	ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
9	adenoma	31.8	APC CTNNB1 KRAS MUTYH
10	pancreatic cancer	31.6	CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR221
11	familial adenomatous polyposis	31.6	APC CTNNB1 KRAS MUTYH
12	melanoma	31.4	MIR141 MIR200C MIR221 MIR27A MIR34A
13	cholangiocarcinoma	31.4	CTNNB1 ERBB2 KRAS MIR141 MIR21 PIK3CA
14	lynch syndrome	31.4	APC CTNNB1 KRAS MUTYH
15	large intestine cancer	31.3	APC CTNNB1 ERBB2 KRAS MUTYH PIK3CA
16	lung cancer susceptibility 3	31.3	APC CTNNB1 ERBB2 KLF6 KRAS PIK3CA
17	bladder cancer	31.2	ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
18	cervical cancer	31.1	CTNNB1 ERBB2 IRF1 MIR21 PIK3CA
19	ovarian cancer	31.1	CTNNB1 ERBB2 KRAS MIR106B MIR141 MIR145
20	glioma	31.1	ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
21	endometrial cancer	31.0	CTNNB1 ERBB2 FGFR2 KRAS MIR200C MUTYH
22	respiratory system cancer	30.9	CTNNB1 ERBB2 KRAS PIK3CA
23	adenoid cystic carcinoma	30.8	CTNNB1 ERBB2 KRAS PIK3CA
24	intrahepatic cholangiocarcinoma	30.8	CTNNB1 FGFR2 KRAS
25	colorectal adenoma	30.8	APC CTNNB1 KRAS MUTYH
26	intestinal disease	30.8	CTNNB1 KRAS MUTYH PIK3CA
27	medulloblastoma	30.8	APC CTNNB1 ERBB2 MIR34A PIK3CA
28	nonalcoholic fatty liver disease	30.8	MIR200C MIR203A MIR21 MIR27A MIR34A
29	kidney cancer	30.8	MIR106B MIR141 MIR200C MIR21 MIR27A
30	pancreatic ductal adenocarcinoma	30.8	MIR141 MIR145 MIR203A MIR21 MIR221
31	leukemia, chronic lymphocytic 2	30.7	KRAS MIR106B MIR145 MIR34A
32	ovarian cancer 1	30.7	ERBB2 KRAS PIK3CA
33	desmoid disease, hereditary	30.6	APC CTNNB1
34	desmoid tumor	30.5	APC CTNNB1
35	attenuated familial adenomatous polyposis	30.4	APC MUTYH
36	gastric cancer, hereditary diffuse	12.8
37	diffuse gastric cancer	12.6
38	microinvasive gastric cancer	12.5
39	stomach carcinoma in situ	12.4
40	epstein-barr virus-associated gastric carcinoma	12.3
41	carcinoma of stomach, salivary gland type	12.2
42	undifferentiated carcinoma of stomach	12.2
43	gastric adenocarcinoma and proximal polyposis of the stomach	11.4
44	li-fraumeni syndrome	11.4
45	li-fraumeni syndrome 2	11.4
46	gastric squamous cell carcinoma	11.1
47	gastric adenosquamous carcinoma	11.1
48	gastric small cell carcinoma	11.1
49	stomach cancer, childhood	11.1
50	gastric linitis plastica	11.1

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)

Active Peptic Ulcer Disease	Acute Cystitis
Deficiency Anemia	Gastric Fundus Cancer
Heart Disease	Intestinal Obstruction
Iron Deficiency Anemia	Neutropenia
Protein-Energy Malnutrition	Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:

Sources

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

³³

#	Description	HPO Frequency	HPO Source Accession
1	stomach cancer ³³		HP:0012126
2	increased level of l-fucose in urine ³³		HP:0410067

Clinical features from OMIM:

613659

UMLS symptoms related to Gastric Cancer:

nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	integument	MP:0010771	9.56	APC CTNNB1 ERBB2 FGFR2 IRF1 KLF6
2	neoplasm	MP:0002006	9.23	APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS

Sources

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Cyramza ¹⁹ ⁵⁰	RAMUCIRUMAB	Eli Lilly	April 2014
FDA Label: Cyramza Disease/s that Drug Treats:gastric cancer Indications and Usage: ¹⁹ CYRAMZAÂ® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3) DrugBank Targets: - Mechanism of Action: ¹⁹ Target: ligand-stimulated activation of VEGF Receptor 2 Action: inhibitor FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
2	Herceptin ¹⁹ ⁵⁰	TRASTUZUMAB	Genentech	October 1998
FDA Label: Herceptin Disease/s that Drug Treats:Breast cancer/gastric cancer Indications and Usage: ¹⁹ Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3) DrugBank Targets: ¹⁶ 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A Mechanism of Action: ¹⁹ Target: human epidermal growth factor receptor 2 protein (HER2) Action: binds with strong affinity for immune response FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
3	Iressa ¹⁹ ⁵⁰	GEFITINIB	AstraZeneca	May 2003
FDA Label: Iressa Disease/s that Drug Treats:Non-Small-Cell Lung Cancer Indications and Usage: ¹⁹ IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. , IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. DrugBank Targets: ¹⁶ 1. Epidermal growth factor receptor, Epidermal growth factor receptor Mechanism of Action: ¹⁹ Target: EGFR tyrosine kinase and other tyrosine kinases, EGFR tyrosine kinase Action: inhibitor FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib., The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Irinotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

100286-90-6, 97682-44-5

60838

Capecitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

61825-94-3

43805 6857599 5310940 9887054

Trastuzumab

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Bevacizumab

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

216974-75-3

Rabeprazole

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

117976-89-3

5029

Levofloxacin

Approved, Investigational

Phase 4,Phase 3,Phase 1

100986-85-4

149096

Clarithromycin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

81103-11-9

84029

Amoxicillin

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

26787-78-0

33613

Esomeprazole

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

161796-78-7, 161973-10-0, 119141-88-7

9568614 4594

Ofloxacin

Approved

Phase 4,Phase 3,Phase 1

82419-36-1

4583

Pravastatin

Approved

Phase 4

81093-37-0

54687

Pantoprazole

Approved

Phase 4,Not Applicable

102625-70-7

4679

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Iron isomaltoside 1000

Approved, Investigational

Phase 4

1370654-58-2

Iron

Approved, Experimental

Phase 4,Phase 3,Not Applicable

7439-89-6, 15438-31-0

27284 23925

Tocopherol

Approved, Investigational

Phase 4,Phase 3,Not Applicable

1406-66-2

14986

Tetracycline

Approved, Vet_approved

Phase 4,Phase 3

60-54-8

5353990

Metronidazole

Approved

Phase 4,Phase 3,Phase 1

443-48-1

4173

Tinidazole

Approved, Investigational

Phase 4,Phase 3

19387-91-8

5479

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

93-14-1

3516

Famotidine

Approved

Phase 4,Phase 1

76824-35-6

3325

Histamine

Approved, Investigational

Phase 4,Phase 1,Not Applicable

51-45-6

774

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

12035

Lansoprazole

Approved, Investigational

Phase 4,Phase 3,Not Applicable

103577-45-3

3883

Dexlansoprazole

Approved, Investigational

Phase 4,Phase 3,Not Applicable

138530-94-6, 103577-45-3

9578005

Omeprazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

73590-58-6

4594

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

437-38-7

3345

Etomidate

Approved

Phase 4

33125-97-2

667484 36339

Propofol

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

2078-54-8

4943

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

51-21-8

3385

Dexmedetomidine

Approved, Vet_approved

Phase 4,Phase 3,Not Applicable

113775-47-6

5311068 68602

leucovorin

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

58-05-9

143 6006

Levoleucovorin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

68538-85-2

Docetaxel

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

114977-28-5

148124

Carboplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

41575-94-4

10339178 38904 498142

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

15663-27-1

2767 441203 84093

Zinc

Approved, Investigational

Phase 4,Phase 2,Not Applicable

7440-66-6

32051

Somatostatin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

38916-34-6, 51110-01-1

53481605

Floxuridine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

50-91-9

5790

Magnesium Sulfate

Approved, Investigational, Vet_approved

Phase 4,Phase 3

7487-88-9

24083

Simethicone

Approved

Phase 4

8050-81-5

Ropivacaine

Approved

Phase 4,Phase 3,Not Applicable

84057-95-4

175805 71273

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Coal tar

Approved

Phase 4

8007-45-2

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2

62-31-7, 51-61-6

681

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

89594 942

Pasireotide

Approved

Phase 4,Phase 1

396091-73-9

9941444

Interventional clinical trials:

(show top 50) (show all 1963)

#	Name	Status	NCT ID	Phase	Drugs
1	Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery	Unknown status	NCT00757640	Phase 4
2	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy	Unknown status	NCT02776527	Phase 4	Apatinib Mesylate Tablets
3	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients	Unknown status	NCT01910948	Phase 4	omega-3 polyunsaturated fatty acids
4	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer	Unknown status	NCT02401971	Phase 4	Thalidomide;CPT-11
5	Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis	Unknown status	NCT02380131	Phase 4	Oxaliplatin plus Capecitabine;Herceptin
6	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis	Unknown status	NCT01962376	Phase 4	Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
7	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.	Unknown status	NCT02638584	Phase 4	Ilaprazole;Rabeprazole
8	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy	Unknown status	NCT01766765	Phase 4
9	Community-based Helicobacter Pylori Eradication	Unknown status	NCT00155389	Phase 4	Helicobacter pylori eradication
10	Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer	Unknown status	NCT02426034	Phase 4	Apatinib
11	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer	Unknown status	NCT01038154	Phase 4	Pravastatin
12	Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?	Unknown status	NCT01621451	Phase 4	aspirin and/or clopidogrel;aspirin and/or clopidogrel
13	Iron Replacement in Oesophagogastric Neoplasia	Unknown status	NCT01927328	Phase 4	Iron isomaltoside 1000
14	A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized，Cross-over Study	Unknown status	NCT02930616	Phase 4
15	Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery	Unknown status	NCT01819961	Phase 4	MCT/LCT and fish oil;MCT/LCT
16	Effect of Helicobacter Pylori on the Availability of Vitamin E and C	Unknown status	NCT00303160	Phase 4	vitamin C & E supplements
17	Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment	Unknown status	NCT03139253	Phase 4	amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
18	Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment	Unknown status	NCT02988089	Phase 4	Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
19	Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection	Unknown status	NCT01308177	Phase 4	Ecabet
20	Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia	Unknown status	NCT00978159	Phase 4	esomeprazole;Famotidine
21	Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection	Unknown status	NCT02249546	Phase 4	N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
22	14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication	Unknown status	NCT01464060	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
23	Optimizing Influenza Vaccination in Surgical Oncology Patients	Unknown status	NCT01698177	Phase 4
24	Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice	Unknown status	NCT01273441	Phase 4	PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
25	Combined Use of Etomidate and Propofol in Painless Gastroscopy.	Unknown status	NCT01913054	Phase 4	Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
26	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	Unknown status	NCT00274885	Phase 4	oxaliplatin
27	Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection	Completed	NCT01914692	Phase 4	Somatostatin
28	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients	Completed	NCT01401075	Phase 4	mistletoe extract;doxifluridine
29	Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor	Completed	NCT01579071	Phase 4
30	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study	Completed	NCT02235246	Phase 4	Magnesium Sulfate;Normal saline
31	Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy	Completed	NCT01653171	Phase 4	Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
32	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia	Completed	NCT01471756	Phase 4
33	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy	Completed	NCT02458573	Phase 4
34	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-	Completed	NCT01234272	Phase 4	morphine;Ropivacaine
35	The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy	Completed	NCT02164448	Phase 4	the dexmedetomidine group;the control group
36	Standard and Immunostimulating Enteral Nutrition in Surgical Patients	Completed	NCT00576940	Phase 4	Reconvan;Peptisorb
37	The Impact of Immunostimulating Nutrition on the Outcome of Surgery	Completed	NCT00558155	Phase 4	peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
38	Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection	Completed	NCT00656968	Phase 4	10-day sequential treatment;10-day concomitant therapy
39	Oncoxin® and Quality of Life in Cancer Patients	Completed	NCT03550482	Phase 4
40	The Effect of Nutritional Counseling for Cancer Patients	Completed	NCT01962272	Phase 4
41	Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03524833	Phase 4	Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
42	Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03521726	Phase 4	Amoxicillin;Rabeprazole, Amoxicillin
43	Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection	Completed	NCT03516669	Phase 4	Clarithromycin;Amoxicillin, Clarithromycin
44	Intraluminal Therapy for Helicobacter Pylori Infection	Completed	NCT03124420	Phase 4	Lansoprazole;Amoxicillin;Clarithromycin
45	10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection	Completed	NCT02959255	Phase 4	Esomeprazole
46	The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study	Completed	NCT00885417	Phase 4	Cravit-based sequential therapy
47	Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori	Completed	NCT01042184	Phase 4	Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
48	The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection	Completed	NCT01032655	Phase 4	susceptibility test guided sequential therapy
49	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
50	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

cisplatin

cisplatin pwdr

docetaxel

floxuridine

fluorouracil

ifosfamide

irinotecan

irinotecan hydrochloride

methotrexate

methotrexate sodium

Cochrane evidence based reviews: stomach neoplasms

Sources

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

#	Genetic test	Affiliating Genes
1	Stomach Cancer ³⁰

Sources

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

⁴²

Lymph Node, Liver, Lung, Breast, Testes, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

²⁰

The Stomach

Sources

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 16568)

#	Title	Authors	Year
1	New metastatic lymph node classification for early gastric cancer should differ from those for advanced gastric adenocarcinoma: Results based on the SEER database. ( 30705892 )	Lin JX...Huang CM	2019
2	Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer. ( 30069742 )	Kao YC...Huang KH	2019
3	Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. ( 30005807 )	Kudou K...Maehara Y	2019
4	Nonhealing gastric ulcer: progression from gastric adenoma to early gastric cancer over 9 years. ( 30176228 )	Probst A...Messmann H	2019
5	The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: A French national database FREGAT. ( 30734393 )	Baudry AS...and the FREGAT Working Group	2019
6	Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer. ( 30315306 )	Kaji K...Yasuda K	2019
7	Correction: Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer. ( 30844907 )	Kaji K...Yasuda K	2019
8	Do subjects with mild or moderate atrophic gastritis or intestinal metaplasia confined to the antrum benefit from gastric cancer surveillance? ( 31030192 )	Quach DT...Gotoda T	2019
9	Polymorphism in Toll-Like Receptors and Helicobacter Pylori Motility in Autoimmune Atrophic Gastritis and Gastric Cancer. ( 31083432 )	De Re V...Cannizzaro R	2019
10	A Diagnostically Challenging Case of Autoimmune Pancreatitis Due to Contamination of the Pathological Specimen with Early Gastric Cancer. ( 30626846 )	Morino M...Mashima H	2019
11	Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. ( 30626829 )	Kono M...Kudo M	2019
12	Nivolumab-related Sclerosing Cholangitis in Gastric Cancer. ( 30626840 )	Motoo Y	2019
13	Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature. ( 30306390 )	Obermair F...Webersinke G	2019
14	Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. ( 31096937 )	Wang F...Xu RH	2019
15	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt? ( 30597479 )	Athauda A...Chau I	2019
16	Response: patient blood management strategies for iron-deficiency anemia management in gastric cancer. ( 30720606 )	Tang GH...Brezden-Masley C	2019
17	Patient Blood Management strategies for iron deficiency anemia management in gastric cancer. ( 30829765 )	Jeric? C...Pera M	2019
18	Gastric cancer and paraneoplastic dermatomyositis as complications of an unrecognized juvenile polyposis syndrome. ( 30873576 )	Schiemer M...Hasselblatt P	2019
19	Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. ( 29589180 )	Hakkaart C...Guilford P	2019
20	Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary diffuse gastric cancer? ( 30466290 )	Munitiz Ruiz V...Parrilla P	2019
21	Establishing a center of excellence for hereditary diffuse gastric cancer syndrome. ( 30618047 )	Drake J...Davis JL	2019
22	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). ( 30745422 )	Lo W...Rudloff U	2019
23	Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. ( 30870726 )	Korivi BR...Bhosale PR	2019
24	INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. ( 30871613 )	Sohn SH...Zang DY	2019
25	Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer. ( 30935944 )	Jacobs MF...Stoffel EM	2019
26	Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. ( 31058107 )	Desuki A...Schimanski CC	2019
27	The benefits of a model of interval comprehensive assessments (MICA) in hereditary cancer Syndromes: Hereditary diffuse gastric cancer (HDGC) as an example. ( 31109593 )	Lynch HT...Diab O	2019
28	What Is the Best Operation for Proximal Gastric Cancer and Distal Esophageal Cancer? ( 31047035 )	Mazer LM...Poultsides GA	2019
29	Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis. ( 30597145 )	Leone PJ...Burke CA	2019
30	Hemi-double stapling technique performed with a transorally inserted anvil for esophagojejunostomy in the surgical treatment of gastric cancer. ( 31099183 )	Ishibashi Y...Fukunaga T	2019
31	More is not always better: triplet chemotherapy and advanced gastric cancer. ( 31101533 )	Fokter-Dovnik N...Smyth EC	2019
32	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. ( 31101534 )	Yamada Y...Terashima M	2019
33	Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. ( 31102009 )	Takahari D...Yamaguchi K	2019
34	Racial/ethnic differences in survival among gastric cancer patients in california. ( 31102083 )	Klapheke AK...Cress RD	2019
35	Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway. ( 31102118 )	Hou G...Liu X	2019
36	Hypoxic Macrophage-Derived VEGF Promotes Proliferation and Invasion of Gastric Cancer Cells. ( 31102128 )	Ma F...Luo S	2019
37	Decreased miR-155-5p, miR-15a, and miR-186 Expression in Gastric Cancer Is Associated with Advanced Tumor Grade and Metastasis ( 31103022 )	Zare A...Ghaedi H	2019
38	Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis. ( 31103997 )	Jagric T...Potrc S	2019
39	Using tRNA halves as novel biomarkers for the diagnosis of gastric cancer. ( 31104009 )	Zhu L...Guo J	2019
40	Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. ( 31104175 )	Miyatani K...Fujiwara Y	2019
41	ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/ HMGA1 axis. ( 31104318 )	Huang B...Li H	2019
42	Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells. ( 31105791 )	Fu X...Guo W	2019
43	A novel circular RNA hsa_circ_0008035 contributes to gastric cancer tumorigenesis through targeting the miR-375/YBX1 axis. ( 31105852 )	Huang S...Yang J	2019
44	Radiomics Signature on Computed Tomography Imaging: Association With Lymph Node Metastasis in Patients With Gastric Cancer. ( 31106158 )	Jiang Y...Li G	2019
45	Downregulation of microRNA-92b-3p suppresses proliferation, migration, and invasion of gastric cancer SGC-7901 cells by targeting Homeobox D10. ( 31106881 )	Li C...Cheng C	2019
46	Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue. ( 31107435 )	Lei G...Zhang Y	2019
47	Differential Helicobacter pylori Plasticity in the Gastric Niche of Subjects at Increased Gastric Cancer Risk. ( 31109082 )	Casarotto M...Zanussi S	2019
48	Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer. ( 31110545 )	Zgodzinski W...Wallner GT	2019
49	KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. ( 31111275 )	Hewitt LC...Grabsch HI	2019
50	The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration. ( 31111481 )	Ghasabi M...Baradaran B	2019

Sources

Genes for Gastric Cancer

Genes related to Gastric Cancer (31 elite genes):

(show top 50) (show all 284)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	1263.43	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Pathways & Interactions Variants (show sections)	1317264 23852704 12378616 (more) 8732100 9639793 20025482 9990480 10408833 10692769 19336228 12373147 11304579 16075282 8855982 7559732 11819821 15639864 11756228 8406987 7676688 11399952 18069630 15942635 11243597 15083323 17693665 9808525
2	CASP10	Caspase 10	Protein Coding	1257.74	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	12010812 11973654 23852704 (more) 15288293 11973654 20025484 14714615
3	IRF1	Interferon Regulatory Factor 1	Protein Coding	1241.04	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	9679752 23852704 19697121 (more) 9679752
4	MUTYH	MutY DNA Glycosylase	Protein Coding	1234.6	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Variants (show sections)	15273732 23852704 16929514 (more) 15273732 18776649 18383848 15180946 19998059
5	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	988.14	Molecular basis known ⁵⁸ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Pathways & Interactions Functions Variants (show sections)	15457249 23852704 20424000 (more) 10829039 9164544 16546744 12143229 7889468 16328035 12530043 7902202 17088902 9703936 11796015 20522955 19636613 15649431 10920922 20038315 18422971 8397058 9892105 19269014 18097546 18441328 14520697 1577221 12548420 1670998 19956838 10754464 20443098 20185938 12739007 12679307 16868827 11857411 10679740 14719064 14535591 15363548 20331976 15501972 16406575 16077916 19337752 8643220 7734322 20368841 20208134 20164030 18258606 8099338 15646832 9544434 7991990 16490596 14991576 1355336 1379062 19156142 7842412 12810831 11776569 17031648 16949920 16718853 11837710 9088037 15668283 11399867 10809364 9732228 7676688 11032920 18224443 16632435 8095412 18483367 16309427 14618618 10950153 9136822 9387254 7912666 8104420 7907612 19536776 19628076 11322480 9758367 9428926 7528080 19783961 16328600 16273224 16121348 9765619 8412172 8102619 1358410 10393360 10223227 9602330 7911025 20082479 17555797 12490974 1350646 19061514 1673870 7901825 1352299 8093216 15517369 7993593 11680933 9058162 7907854 11948459 11396210 15928192 1353880 7907434 1979253 19034345 11776853 8098198 1970690 2157713 1346086 12579211 2098274 18835621 18413839 9570245 2386738 19479974 18172343 8330300 1350789 10619912 7882346 8103127 1676988 20430735 12692839 1348293 10446693 9927058 7753016 16187281 10618628 7775839 8697969 9275549
6	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	935.6	Molecular basis known ⁵⁸ Pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Pathways & Interactions (show sections)	10394936 11325814 23852704 (more) 11325814 16391783 18381441 17459342 20331976 1844251 10626794 18636142 7791773 15796961 19387476 17697126 17505008 16773196 7562911 16273224 15754011 12684685 12739007 19212647 8205545 12684693
7	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	932.26	Molecular basis known ⁵⁸ Pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15608678 23852704 15016963 (more) 15520168 17673550 22658544 22729222 23100325 26266975 26266985 22729224 22729223 15608678 12569555 15784156 17680560 17935137 19062713
8	KLF6	Kruppel Like Factor 6	Protein Coding	920.46	Molecular basis known ⁵⁸ Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)	15824733 23852704
9	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	766.09	Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Pathways & Interactions Variants (show sections)	8439212 7773929 20805368 (more) 22683711 20949522 22499344 17332249 21079152 23852704 16187281 15994075 16007118 19545448 19639197 9301460 17697521 19013893 14534542 20358631 19755509
10	CTNNB1	Catenin Beta 1	Protein Coding	454.9	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Pathways & Interactions (show sections)	23852704 12452049 16830381 (more) 11147171 11493330 12439911 11241321 12598910 15128072 17663505 10408833 16356709 15682444 11125285 20025482 18835621 12966349 16075282 14625188 19102422 14978364 12692839 11163116 20372837 12383223 15609380 12721245 15138556 15896469 10604738 19958059 19413886 12548420 11756228 16311123 19688824 9765619 11747475 18705344 16132582 17163846 10485468 11604997 15467739 7629993 19223545 18806748 18330950 15245777 11788899 19783961 19051296 15609344 19798449 17297461 17400182 16521229 14662019 11605001 19749785 19475529 17520678 17396032 15895459 15116100 8806677 12460462 12216071 16651426 15754012 7862112 18765951 15182428 17952562 17295679 11712074 12481159
11	MIR21	MicroRNA 21	RNA Gene	407.77	Causal ⁴⁸ Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	18794849 16461460
12	MIR25	MicroRNA 25	RNA Gene	407.05	Causal ⁴⁸ Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	19153141 16461460
13	MIR221	MicroRNA 221	RNA Gene	406.92	Causal ⁴⁸ Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	19153141 16461460
14	MIR203A	MicroRNA 203a	RNA Gene	360.49	Causal ⁴⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	21063914
15	MIR34A	MicroRNA 34a	RNA Gene	357.5	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	21112772
16	MIR145	MicroRNA 145	RNA Gene	357.23	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19439999
17	MIR141	MicroRNA 141	RNA Gene	357.23	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19363643
18	MIR27A	MicroRNA 27a	RNA Gene	357.23	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	18789835
19	MIR200C	MicroRNA 200c	RNA Gene	357.19	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	21114921
20	MIR106B	MicroRNA 106b	RNA Gene	357.15	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19153141
21	MIR20A	MicroRNA 20a	RNA Gene	357.05	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	21112772
22	MIR222	MicroRNA 222	RNA Gene	356.99	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19153141
23	MIR143	MicroRNA 143	RNA Gene	356.99	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19439999
24	MIR451A	MicroRNA 451a	RNA Gene	356.85	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19318487
25	MIR215	MicroRNA 215	RNA Gene	356.85	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	21119604
26	MIR93	MicroRNA 93	RNA Gene	356.76	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19153141
27	MIR196B	MicroRNA 196b	RNA Gene	356.64	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	20662076
28	MIR192	MicroRNA 192	RNA Gene	350	Causal ⁴⁸	21119604
29	MIR150	MicroRNA 150	RNA Gene	350	Causal ⁴⁸	20067763
30	MIR122	MicroRNA 122	RNA Gene	350	Causal ⁴⁸	19607815
31	MIR15B	MicroRNA 15b	RNA Gene	350	Causal ⁴⁸	18449891
32	MUC2	Mucin 2, Oligomeric Mucus/Gel-Forming	Protein Coding	183.5	Experimental evidence: Expression ⁴⁰ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Pathways & Interactions (show sections)	27835575 15378790 19329938 (more) 16820924 10604660 20062084 9308730 15248919 17387567 15637340 15807306 18573283 7515385 16185290 11278696 14742272 15086835 17559374 15737028 14758553 11745219 15354218 11775866 16733847 16988760 12498221 10681391 11889602 18938748 12719460 9583726 10620506 19102008 16807756 11574777 20492327 18521835 14719100 12692839 11101634 18507055 17213039 14525978 10699992 15309883 10592051 12490305 15071739 14636271 14576935
33	GACAT2	Gastric Cancer Associated Transcript 2	RNA Gene	175.49	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications Gene name (show sections)	28105191 24961350
34	GACAT3	Gastric Cancer Associated Transcript 3	RNA Gene	172.3	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Gene name (show sections)	27644247 27246953 24969565
35	FENDRR	FOXF1 Adjacent Non-Coding Developmental Regulatory RNA	RNA Gene	169.22	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)	25167886
36	LINC00673	Long Intergenic Non-Protein Coding RNA 673	RNA Gene	169.1	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)	29221147 28214253
37	GAPLINC	Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA	RNA Gene	168.27	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	27729869 26286476 25277524
38	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	167.35	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	29683069 29417297 29080815 (more) 28970725 27900563 27751178 27246953 26964077 26935047 26384301 26237576 26187665 26136075 26096073 25968902 25640751 25612617 25280565 25063030 24949306 24775712 24757675 24130837 23847441
39	FRGCA	FOXM1-Regulated, Gastric Cancer Associated	RNA Gene	166.04	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications Gene name (show sections)	26261500
40	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	165.96	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	28535628 28239816 27134049 (more) 26825578 25674211 25561974 24833871 24757675 23143645
41	YAP1	Yes Associated Protein 1	Protein Coding	165.76	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)	27835600
42	EGFLAM-AS1	EGFLAM Antisense RNA 1	RNA Gene	164.86	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications Gene name (show sections)	26537802
43	CYTOR	Cytoskeleton Regulator RNA	RNA Gene	162.42	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29339419 29156518 27592063 (more) 27246953 27143813 26799422 26538117 26237576 25391424 24523021
44	GHET1	Gastric Carcinoma Proliferation Enhancing Transcript 1	RNA Gene	162.4	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ ¹⁵	28578256 28577495 27246953 (more) 26884908 26096073 24397586
45	UCA1	Urothelial Cancer Associated 1	RNA Gene	162.05	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29723509 29516678 29212166 (more) 28843497 28569779 28423525 28075173 27694794 27329842 27056384 26935047 26722487 26718650 25903045 25769450 25694351 16914571
46	PVT1	Pvt1 Oncogene	RNA Gene	161.79	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28258379 28122299 27756785 (more) 26925791 26096073 25956062 25890171 25258543
47	ZFAS1	ZNFX1 Antisense RNA 1	RNA Gene	161.39	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29424266 28285404 27654478 (more) 27246976
48	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	161.18	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	27121324 27027260 25636450 (more) 24810364
49	TINCR	TINCR Ubiquitin Domain Containing	Protein Coding	160.89	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28744139 27893425 25728677
50	GAS5	Growth Arrest Specific 5	RNA Gene	160.87	Experimental evidence: Mutation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29602737 29098549 27827524 (more) 27466992 27246953 26278580 25959498 24884417

Sources

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

⁷⁶ (show all 19)

#	Symbol	AA change	Variation ID	SNP ID
1	APC	p.Gly817Cys	VAR_005035
2	APC	p.Ile880Thr	VAR_005036	rs140029598
3	APC	p.Asn942Asp	VAR_005039
4	APC	p.Gly1120Glu	VAR_005042	rs28933379
5	APC	p.Arg1171His	VAR_005043	rs372481703
6	APC	p.Phe1197Ser	VAR_005045
7	APC	p.Ile1259Thr	VAR_005046
8	APC	p.Gly1312Glu	VAR_005050
9	APC	p.Val1326Ala	VAR_005052
10	CASP10	p.Met147Thr	VAR_037428	rs121909776
11	IRF1	p.Met8Leu	VAR_065134	rs121912469
12	IRF1	p.Trp11Arg	VAR_065135	rs121912470
13	KRAS	p.Gly12Val	VAR_006840	rs121913529
14	KRAS	p.Gly12Asp	VAR_016026	rs121913529
15	KRAS	p.Gly12Ser	VAR_016028	rs121913530
16	KRAS	p.Gly13Asp	VAR_016029	rs112445441
17	KRAS	p.Ala59Thr	VAR_016030	rs121913528
18	KRAS	p.Lys5Asn	VAR_064849	rs104894361
19	MUTYH	p.Pro402Ser	VAR_026049	rs121908382

ClinVar genetic disease variations for Gastric Cancer:

⁶ (show top 50) (show all 186)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	APC	NM_000038.5(APC): c.3359G> A (p.Gly1120Glu)	single nucleotide variant	Pathogenic	rs28933379	GRCh37	Chromosome 5, 112174650: 112174650
2	APC	NM_000038.5(APC): c.3359G> A (p.Gly1120Glu)	single nucleotide variant	Pathogenic	rs28933379	GRCh38	Chromosome 5, 112838953: 112838953
3	APC	NM_000038.5(APC): c.3199C> T (p.Gln1067Ter)	single nucleotide variant	Pathogenic	rs137854571	GRCh37	Chromosome 5, 112174490: 112174490
4	APC	NM_000038.5(APC): c.3199C> T (p.Gln1067Ter)	single nucleotide variant	Pathogenic	rs137854571	GRCh38	Chromosome 5, 112838793: 112838793
5	APC	NM_000038.5(APC): c.1660C> T (p.Arg554Ter)	single nucleotide variant	Pathogenic	rs137854573	GRCh37	Chromosome 5, 112164586: 112164586
6	APC	NM_000038.5(APC): c.1660C> T (p.Arg554Ter)	single nucleotide variant	Pathogenic	rs137854573	GRCh38	Chromosome 5, 112828889: 112828889
7	APC	NM_000038.5(APC): c.2805C> A (p.Tyr935Ter)	single nucleotide variant	Pathogenic	rs137854575	GRCh37	Chromosome 5, 112174096: 112174096
8	APC	NM_000038.5(APC): c.2805C> A (p.Tyr935Ter)	single nucleotide variant	Pathogenic	rs137854575	GRCh38	Chromosome 5, 112838399: 112838399
9	MTHFR	NM_005957.4(MTHFR): c.665C> T (p.Ala222Val)	single nucleotide variant	drug response	rs1801133	GRCh37	Chromosome 1, 11856378: 11856378
10	MTHFR	NM_005957.4(MTHFR): c.665C> T (p.Ala222Val)	single nucleotide variant	drug response	rs1801133	GRCh38	Chromosome 1, 11796321: 11796321
11	MUTYH	NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys)	single nucleotide variant	Pathogenic	rs34612342	GRCh37	Chromosome 1, 45798475: 45798475
12	MUTYH	NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys)	single nucleotide variant	Pathogenic	rs34612342	GRCh38	Chromosome 1, 45332803: 45332803
13	MUTYH	NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp)	single nucleotide variant	Pathogenic/Likely pathogenic	rs36053993	GRCh37	Chromosome

Gastric Cancer (GASC)

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Characteristics:

HPO:

Classifications:

External Ids:

Summaries for Gastric Cancer

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)

Graphical network of the top 20 diseases related to Gastric Cancer:

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

Clinical features from OMIM:

UMLS symptoms related to Gastric Cancer:

MGI Mouse Phenotypes related to Gastric Cancer:

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

Publications for Gastric Cancer

Articles related to Gastric Cancer:

Genes for Gastric Cancer

Genes related to Gastric Cancer (31 elite genes):

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

ClinVar genetic disease variations for Gastric Cancer:

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :